Business Wire

AMP-ROBOTICS

30.5.2022 08:02:04 CEST | Business Wire | Press release

Share
​​AMP Robotics Continues European Expansion

AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, continues to expand its presence in Europe to meet the demand for its AI and automation solutions and provide dedicated local support and service for the market. The company is exhibiting at IFAT 2022 , May 30-June 3 in Munich, for the first time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005046/en/

AMP installed its first AI-guided robotics systems in the UK and Ireland with Recyco in September 2021 and has since deployed more recycling solutions throughout Europe, including at FCC Medio Ambiente/Environment in Spain. AMP has grown its team to include sales support, training, service, and marketing, in addition to direct sales staff focused on serving Austria, Belgium, France, Germany, Luxembourg, The Netherlands, and Switzerland, along with the UK and Ireland.

“AMP is the leading brand in robotics, and that was an important factor for us in choosing a solution to improve our sorting productivity and efficiency,” said Alfredo Vigre, project manager, Waste Treatment Department, FCC Medio Ambiente/Environment. “We tested the robot prior to implementation and were pleased with its ability to recognize and recover materials that optical sorters cannot. It’s been fast and effective, and a great tool for quality control.”

AMP provides a portfolio of recycling solutions powered by its industry-leading neural network, which is built on a data engine that has recognized more than 50 billion containers and packaging types ​​​​​in real-world conditions. AMP Cortex™ is the company’s high-speed robotic sorting system with approximately 230 deployments in more than 80 facilities across three continents. AMP’s install base is the largest known fleet of recycling robots in the world, creating the most expansive neural network of field data for recycled materials. AMP Vision™ is a modular computer vision system that helps operators understand material flow throughout key stages of sorting operations and serves as a quick and efficient alternative to manual sampling audits. When integrated with AMP Clarity™, the company’s material characterization and robot performance software solution, users can monitor real-time material characterization and performance measurement throughout a facility. AMP recently introduced new Clarity features including mass estimation; robot pick assignments, alerts, and status tracking; and expanded reporting capabilities.

“We’re seeing strong interest in and satisfaction with our AI and robotics technology here in Europe thanks to our technological leadership,” said Gary Ashburner, general manager, Europe, for AMP Robotics. “Our AI platform, AMP Neuron, continues to achieve breakthroughs in data accuracy and classification of different polymers, form factors, and other packaging types, which is helping our customers take a more data-driven approach to increasing recovery, lowering costs, and optimizing operations.”

At IFAT, AMP’s European-based team will provide live demonstrations of the company’s vision system for material characterization at booth 546 in Hall B6.

“As we continue to scale our business and innovate new ways to improve the economics of recycling, we’re committed to the European market and our growing customer base there,” said Matanya Horowitz, founder and CEO of AMP Robotics. “Our efforts to modernize Europe’s recycling infrastructure are important to our global investors, and critical to realizing our vision of a world without waste.”

About AMP Robotics® Corp.

AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, high-value materials from construction and demolition debris, and valuable feedstocks from organic material.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye